Floatz logo

Inotuzumab Ozogamicin

Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia

M.D. Anderson Cancer Centerantibody_drug_conjugatePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

86 Active assets in the Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
City of Hope Medical Center
Phase 3BBB
Nilotinib
Novartis Pharmaceuticals
Phase 4BBB
Fludarabine
Fred Hutchinson Cancer Center
Phase 3BBB
Therapeutic Allogeneic Lymphocytes
University of Chicago
Phase 2BBB
Romidepsin
Center for International Blood and Marrow Transplant Research
Phase 2BBB

View all 50 →

Same molecule, other indications

Inotuzumab Ozogamicin is also rated in:

acute lymphoblastic leukemiaDormant
BB
Indicative ·
69 / 100
View asset →
B-cell acute lymphoblastic leukemiaDormant
BB
Indicative ·
68 / 100
View asset →
B Lymphoblastic LymphomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →